ImmunOs Therapeutics develops bispecific antibody immunotherapies that direct a patient’s immune system to target cancer cells and inflammatory disease antigens. Their lead candidate, IOS‑1002, combines engineered binding domains and an optimized Fc region to enhance specificity, potency, and half‑life, and is currently in Phase 1 trials, including combination studies with checkpoint inhibitors. The platform aims to provide pharmaceutical partners and clinicians with next‑generation, combination‑ready treatments for solid tumors and rheumatic diseases.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3ODPFounders
Product
Problem
Current treatments for many cancers and inflammatory diseases rely on non-specific therapies that often produce limited efficacy and significant side effects, leaving patients with unmet medical needs.
Solution
ImmunOs Therapeutics focuses on creating novel immunotherapeutic agents that harness and direct the patient’s own immune system to attack tumors and modulate pathological inflammation. Their lead program, IOS‑1002, is a bispecific antibody designed to simultaneously engage immune effector cells and tumor or inflammatory targets, enhancing specificity and potency. The platform leverages advanced protein engineering to generate molecules with optimized binding affinities, favorable pharmacokinetics, and reduced immunogenicity. Preclinical studies have demonstrated strong anti‑tumor activity, and the company has progressed IOS‑1002 into first‑in‑human Phase 1 trials, including combination studies with checkpoint inhibitor KEYTRUDA® (pembrolizumab). By integrating rigorous clinical development with strategic collaborations, ImmunOs aims to deliver next‑generation immunotherapies for solid tumors and rheumatic diseases.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology and inflammatory disease pipelines, as well as clinical investigators and healthcare providers seeking innovative immunotherapy options.
Features
- Bispecific antibody architecture that links immune effector cells to disease‑specific antigens for targeted activity
- Engineered Fc region to modulate effector functions and extend serum half‑life
- Combination-ready design enabling synergistic use with established checkpoint inhibitors
- Robust preclinical validation pipeline showing in‑vivo efficacy and safety across multiple tumor models
- First‑in‑human Phase 1 clinical program with regulatory approval and ongoing dose‑escalation studies